Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients

American Journal of Hypertension

Volumn 26, Issue 12, 2013, Pages 1452-1458

  Hayek, Salim S ^a   Abdou, Mahmoud H ^a   Demoss, Benjamin D ^a   Legaspi, Juan M Ortega ^a   Veledar, Emir ^b   Deka, Anjan ^a   Krishnan, Sandeep K ^a   Wilmot, Kobina A ^a   Patel, Aalok D ^a   Kumar, Vikas R ^b   Devireddy, Chandan M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood pressure; Hypertension; Prevalence; Renal denervation; Resistant hypertension; SYMPLICITY HTN

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; METHYLDOPA; MINOXIDIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

EID: 84890544805     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt132     Document Type: Article

References (24)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125:e2-e220.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
3. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL, REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34:1204-1214.
4. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
6. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
7. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
8. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35:528-535.
9. Massierer D, Oliveira AC, Steinhorst AM, Gus M, Ascoli AM, Goncalves SC, Moreira LB, Correa V Jr, Nunes G, Fuchs SC, Fuchs FD. Prevalence of resistant hypertension in non-elderly adults: prospective study in a clinical setting. Arquivos Brasileiros de Cardiologia 2012; 99:630-635.
10. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
11. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
12. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
13. McAdam-Marx C, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Therapeut 2009; 31:8.
14. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR, ASCOT Investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29:2004-2013.
15. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
16. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, Laragh JH, McInnes G, Schork AM, Smith B, Weber M, Zanchetti A. VALUE trial: Long-Term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-548.
17. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4:393-404.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
19. Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. Cost-effectiveness and clinical effectiveness of catheterbased renal denervation for resistant hypertension. J Am Coll Cardiol 2012; 60:1271-1277.
20. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol 2012; 60:2422-2424.
21. Dougherty W, Warren J. Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients With Systolic Blood Pressure Between 140-160 mm Hg. .
22. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Therapeut 2009; 31:1116-1123.
23. Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013; 6:1-9.
24. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55:147-152.